Toloxatone

CHEMBL18116 Phase 4 Aprobado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
207.2 g/mol
LogP
1.2
Phase
4

Toloxatone is a selective and reversible monoamine oxidase A (MAO-A) inhibitor that prevents the oxidative deamination of serotonin and norepinephrine, increasing their synaptic concentrations and producing antidepressant effects. It is used for the treatment of depression and has the advantage over irreversible MAO inhibitors of lower risk for tyramine-induced hypertensive crisis (cheese effect) due to its reversibility and selectivity. Its RIMA (reversible inhibitor of MAO-A) profile allows competitive displacement by dietary tyramine, reducing the dietary restrictions required.

Peso molecular

207,2300 g/mol

LogP

1,20

TPSA

49,80 Ų

Regla de cinco de Lipinski

Cumple

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Estructura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Cc1cccc(N2CC(CO)OC2=O)c1

InChI

InChI=1S/C11H13NO3/c1-8-3-2-4-9(5-8)12-6-10(7-13)15-11(12)14/h2-5,10,13H,6-7H2,1H3

Molecular Formula

C11H13NO3

HBD / HBA

1 / 3

Enlaces Rotables

2

Átomos Pesados

15

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

Toloxatone is a selective and reversible monoamine oxidase A (MAO-A) inhibitor that prevents the oxidative deamination of serotonin and norepinephrine, increasing their synaptic concentrations and producing antidepressant effects. It is used for the treatment of depression and has the advantage over irreversible MAO inhibitors of lower risk for tyramine-induced hypertensive crisis (cheese effect) due to its reversibility and selectivity. Its RIMA (reversible inhibitor of MAO-A) profile allows competitive displacement by dietary tyramine, reducing the dietary restrictions required.

Yes, Toloxatone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL18116. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 34521. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.